Table 1. Patient characteristics.
| No ATG | ATG | P value | |
|---|---|---|---|
| N | 48 | 50 | |
| Number of males | 20 (42) | 32 (64) | 0.026 |
| Median age at transplant (range) | 47 (25, 63) | 48 (19, 61) | 0.57 |
| Donor type | |||
| Match related | 48 | 0 | — |
| Match unrelated | 0 | 50 | |
| Conditioning regimen | |||
| CY/TBI, BU/CY, VP16/TBI | 41 (85) | 39 (78) | 0.34 |
| BU/Flu | 7 (15) | 11 (22) | |
| GVHD prophylaxis | |||
| Tacrolimus | 14 (29) | 25 (50) | 0.07 |
| CYA | 12 (25) | 13 (26) | |
| CYA→Tacrolimus | 20 (42) | 12 (24) | |
| Sirolimus | 2 (4) | 0 | |
| ATG dose | |||
| 10 mg/kg adjusted ideal body weight | N/A | 26 | — |
| 7.5 mg/kg adjusted ideal body weight | N/A | 24 | |
| Stem cell source | |||
| PBSC | 46 (96) | 28 (56) | <0.001 |
| Mean cell dose ± s.d. | |||
| CD3 (108 cells/kg) | 3.69 ± 2.06 | 2.57 ± 2.27 | 0.012 |
| CD34 (106 cells/kg) | 5.09 ± 1.76 | 5.10 ± 2.68 | 0.98 |
| Remission status | |||
| 1st CR | 29 (60) | 30 (60) | 0.97 |
| 2nd CR | 14 (29) | 14 (28) | |
| ≥ 3rd CR | 5 (10) | 6 (12) | |
| Diagnosis at time of transplant | |||
| ALL | 7 (14) | 9 (18) | 0.19 |
| AML | 32 (67) | 30 (60) | |
| MDS | 6 (13) | 11 (22) | |
| MF | 3 (6) | 0 (0) | |
Abbreviations: Flu = fludarabine; MF = myelofibrosis; MDS = myelodysplastic syndrome. Regimens used: CY/TBI-TBI, six fractions of two Gray (Gy) each, day − 6 to − 4, and CY 60 mg/kg i.v., day − 3 and − 2; BU/CY-BU 0.8 mg/kg i.v. every 6 h, day − 7 to − 4 and CY 60 mg/kg i.v., day − 3 and − 2; BU/Flu-BU 130 mg/m2 i.v. daily, day − 5 to − 2, and Flu 40 mg/m2 i.v., day − 5 to − 2; VP16/TBI- TBI 7 fractions two Gy each and etoposide (VP16) 60 mg/kg i.v., one dose. GVHD prophylaxis: Tacrolimus target level 5–12 ng/mL; CYA, target level 250–350 ng/mL, both starting day − 2, generally tapered following day 100. CYA→Tacrolimus, i.v. CYA transitioned to oral tacrolimus following engraftment. Calcinuerin inhibitors administered with MTX 15 mg/m2 i.v. on day 1, and 10 mg/m2 on days 3, 6 and 11 and leucovorin rescue. In patients who could not tolerate MTX, mycophenolate mofetil 15 mg/kg PO/i.v. twice daily was given from day 0 to 30. Sirolimus target level 5–10 ng/mL, day − 2 to day 100. Percentages in parentheses.